Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jan 26, 2026
Reporting period
Not applicable
Filed with the SEC
Jan 27, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-024826
Filed / recorded
Jan 27, 2026, 10:04 PM UTC
Added to OQRO
Oct 7, 2026, 6:56 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Larimar Therapeutics, Inc.
Issuer CIK
1374690
Ticker
LRMR
Reporting person
Carole Ben-maimon
Relationship
Director, Officer
Officer title
President and CEO
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Jan 26, 2026
Transaction code
A
Shares / units
600,600
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
600,600
Ownership form
Direct
Amendment
No
Footnotes from the filing
The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.